Skip to main content

Psoriatic arthritis

RheumNow Podcast – Pounds of Prevention (3.5.2021)

Mar 04, 2021

Dr. Jack Cush reviews and discusses nearly a dozen news reports and journal articles from the past week on RheumNow.com.

Read Article
News Feature: MAXIMISE Trial - Secukinumab Efficacy in Psoriatic Spondylitis Patients https://t.co/34RU4OSaRi

Dr. John Cush @RheumNow( View Tweet )

Feb 28, 2021

MAXIMISE Trial - Secukinumab Efficacy in Psoriatic Spondylitis Patients

Feb 26, 2021

The results of the novel MAXIMISE trial have been published, demonstrating that secukinumab significantly improved axial signs and symptoms in psoriatic arthritis patients with axial manifestations with inadequate NSAID response.

Read Article
We are three weeks out from RheumNow Live. Are you planning on attending? https://t.co/vJlU0Z3Q3x

Dr. John Cush @RheumNow( View Tweet )

Feb 26, 2021

RheumNow Podcast – Sweet Lies or Hard Truths? (2.26.2021)

Feb 26, 2021

Dr. Jack Cush reviews and discusses the news and Journal reports from the past week on RheumNow.com.

Read Article
Psoriasis has greatest risk of MTX liver dz - a Danish Population study of PsO, PsA & RA pts taking MTX. Risk of liver Dz was most in PsO, followed by PsA, then RA. PsO had 1.6-3.4 fold risk (mild-severe) liver dz (vs RA). PsA was 1.3-1.6x higher) https://t.co/9YiGqVr66w

Dr. John Cush @RheumNow( View Tweet )

Feb 25, 2021
RWCS Highlights - Day 3 -Psoriatic Arthritis -Evidence Based Medicine: Diet and Rheumatic Diseases -Hot topics in Allergy/Immunology -Pediatric Rheumatology – past, present, and future https://t.co/CaKAyhxId3 https://t.co/5m882bcTOo
Dr. John Cush @RheumNow( View Tweet )
Feb 16, 2021

RWCS Highlights - Day 3

Feb 15, 2021

Day 3 report from the 2021 RWCS meeting in Maui (and virtually) includes pearls from the PsA 2020 Year in Review; fact vs. fiction on evidence based medicine: diet and rheumatic diseases; hot topics in allergy/immunology; and pediatric rheumatology highlights.

Read Article
EXCEED study in #PsA shows lower responses in women (vs men) treated with either secukinumab or adalimumab. Question is, why? @RWCSmtg @JointMD https://t.co/LFBQi1jtiu
Dr. John Cush @RheumNow( View Tweet )
Feb 12, 2021
In #PsA does it matter if you're on background MTX when treated with ixekizumab or adalimumab? MTX does augment ADA responses but it's not needed with IXE @RWCSmtg @JointMD https://t.co/9GpKjLS4ao
Dr. John Cush @RheumNow( View Tweet )
Feb 12, 2021
No increased risk of cancer with TNFi use in PsA patients @RWCSmtg @JointMD https://t.co/7VSI1Fd1hw
Dr. John Cush @RheumNow( View Tweet )
Feb 12, 2021
Partial control of #PsA on MTX- Control study shows that adding adalimumab is superior to just escalating MTX @RWCSmtg @JointMD https://t.co/nDWzf4HYwp
Dr. John Cush @RheumNow( View Tweet )
Feb 12, 2021
Drs. Kavanaugh, Ruderman, Ogdie at @RWCSmtg on the multiple domains of psoriatic arthritis #PsA @JointMD https://t.co/3uS6JxdfIR
Dr. John Cush @RheumNow( View Tweet )
Feb 12, 2021

Weekly Semaglutide for Weight Loss in Adults

Feb 11, 2021

NEJM has reported the results of a trial showing semaglutide once weekly plus lifestyle intervention was associated with sustained, weight loss in overweight or obese adults; such that nearly one-third lost over 20% of their body weight.



Semaglutide, a once weekly glucagon-like

Read Article

ACR Promotes New COVID-19 Vaccine Clinical Guidance for Rheumatic Patients

Feb 10, 2021

The American College of Rheumatology has published a draft guidance on the use of COVID-19 vaccination in rheumatic disease and musculoskeletal disease patients, based on the efforts of the North American Task force. The document provides guidance to rheumatology providers on the use of the

Read Article

We are excited to announce that Dr. Eric Ruderman ( @JointMD) will be speaking on advancing treatments in psoriatic arthritis at RheumNow Live, March 20-21. There's still time to sign up. https://t.co/vJlU0Z3Q3x https://t.co/T0V8JIygyA

Dr. John Cush @RheumNow( View Tweet )
Feb 09, 2021

Comorbidity and Drugs Drive COVID-19 Severity and Survival in Rheumatic Disease

Feb 09, 2021

While comorbidities are associated with severe COVID-19 infection, it appears they also influence severity and survival in rheumatic disease (RMD), according to a a French cohort study,



Analysis of a French RMD cohort with SARS-CoV-2 infection analyzed the effect of inflammatory

Read Article
QD Clinic Podcast from Last week. iTunes https://t.co/FHJv01AAbC or SoundCloud https://t.co/dfSTkSbY2d QD Clinics (123-127; Feb 5) QD127 - Chronic Monarthritis QD126 - Fever by the Numbers QD125 - "What Were You Thinking" QD124 - No Win Consults QD123 - When RA Meets UC https://t.co/ReOFOVooje
Dr. John Cush @RheumNow( View Tweet )
Feb 08, 2021

RheumNow Podcast – Tofacitinib Safety Concerns (2.5.2021)

Feb 05, 2021

Dr. Jack Cush reviews and discusses the news and journal reports from the past week on RheumNow.com.

Read Article
Consults in Cars--have telehealth consults gone too far? https://t.co/INbKZ3xxty https://t.co/X2RwktCd2U
Dr. John Cush @RheumNow( View Tweet )
Feb 03, 2021

Low Persistence of Biologics in Psoriatic Arthritis

Feb 02, 2021

A longitudinal observational cohort study of psoriatic arthritis (PsA) patients treated with biologic therapy finds relatively low persistence of selected biologic therapy in PsA patients



Analysis of PsA patients (n=2301) from a large healthcare provider database, seen between 2002

Read Article
Low Persistence of Biologics in Psoriatic Arthritis A longitudinal observational cohort study of psoriatic arthritis (PsA) patients treated with biologic therapy finds relatively low persistence of selected biologic therapy in PsA patients. https://t.co/CzQnpAnttW https://t.co/uYU778rwod
Dr. John Cush @RheumNow( View Tweet )
Feb 02, 2021
Abbvie has released data from KEEPsAKE-1 and KEEPsAKE-2 studies (1407 pts) showing Risankizumab (IL--23 inhibitor) is effective in Psoriatic arthritis; RIS Rx pts achieved ACR20 of 57% and 51% at week 24 (vs PBO 34% and 27%; p<0.001) https://t.co/wPQMqLnhOO

Dr. John Cush @RheumNow( View Tweet )

Feb 01, 2021
Sign up for RheumNow Live, March 20 and 21st. CME credits available. https://t.co/uwxOVh142F https://t.co/GqkCLBGl62
Dr. John Cush @RheumNow( View Tweet )
Jan 31, 2021
Several studies have shown that Xray progression has lessened in recent yrs - presumeably from more aggressive Rx by Rheums! Still - Predictors of Xray long term damage = high ESR/CRP, baseline xray damage, -CCP/RF positivity https://t.co/2iaMiaquEV https://t.co/cgEP4QBvL4

Dr. John Cush @RheumNow( View Tweet )

Jan 29, 2021
×